Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$4.40
$0.20(4.55%)
At close: 4:00 PM EDT
$4.40
$0.20(4.55%)
Day’s Range― - ―
52-Week Range$4.35 - $18.40
Previous Close$4.6
Volume4.70K
Average Volume (3M)2.40K
Market Cap
$64.51M
Enterprise Value$68.44
Total Cash (Recent Filing)$5.65M
Total Debt (Recent Filing)$1.09M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
NIH-backed Cannabinoid PipelineThe NIH grant provides two years of non-dilutive support for rare cannabinoid production, analog development and preclinical testing. This expands the pipeline beyond NCT and may improve partnership potential if the platform produces viable pharmaceutical candidates.
Reduced LeverageLower debt and moderate leverage reduce fixed financial obligations while the company remains pre-commercial. This gives eXoZymes more balance-sheet flexibility than a heavily debt-funded biotechnology company, although losses still pressure equity.
Improved Development FundingRecent financing provides capital for N-trans-caffeoyltyramine, additional product candidates, research and working capital. Greater funding visibility can help sustain development milestones over the next several quarters, despite the associated dilution.
Bears Say
No Commercial RevenueThe absence of revenue indicates that the company has not yet demonstrated commercial product-market fit or recurring demand. Continued reliance on pipeline advancement and external funding makes future performance dependent on successful development and commercialization.
Persistent Losses And Cash BurnLarge recurring losses and negative operating cash flow require ongoing financing to maintain operations and fund research. Unless revenue or partnerships emerge, continued burn could constrain development pace and increase dependence on potentially dilutive capital raises.
Warrant-driven Dilution RiskWarrant-heavy financing can increase the future share count and weaken existing ownership if instruments are exercised. The reset provision may intensify dilution in a lower-price financing scenario, complicating capital planning and potentially limiting financing flexibility.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $4.35 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
eXoZymes’s market cap is $64.51M.
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Nov 12, 2026 which is in 78 days.
How were eXoZymes’s earnings last quarter?
eXoZymes released its earnings results on Aug 20, 2026. The company reported -$0.332 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 9,281,359 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
eXoZymes reported an EPS of -$0.332 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
eXoZymes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Company Description
eXoZymes
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
15.58% Insiders
0.45% Mutual Funds
― Other Institutional Investors
82.70% Public Companies and
Individual Investors